Expresses opinion on the strategic plans of biotechnology firms to deal with the challenges facing biotechnology vendors in the U.S. Comments on biotechnology firms that sell to the pharmaceutical industry; Implementation of the drug discovery strategy; Transition to a hardware/software solutions provider.